US OptionsDetailed Quotes
SCPH250516C5000
- 0.03
- 0.000.00%
15min DelayClose May 7 16:00 ET
0.00High0.00Low
0.03Open0.03Pre Close0 Volume1.13K Open Interest5.00Strike Price0.00Turnover281.02%IV108.71%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0746Delta0.1334Gamma80.33Leverage Ratio-0.0080Theta0.0000Rho5.99Eff Leverage0.0005Vega
scPharmaceuticals Stock Discussion
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Cash and cash equivalents of $75.7 million as of December 31, 2024
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overloa...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
·1 min ago
ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
Thursday, 6th March at 4:01 pm
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome
FUROSCIX is expected to be available ...
ScPharmaceuticals Inc - Observes Variability in Scp-111 Product Testing
Snda Submission for Scp-111 May Be Delayed
No comment yet